|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||20.87|
|Forward Dividend & Yield||1.12 (2.29%)|
|1y Target Est||N/A|
Emerson (EMR) recently clinched an automation systems and services contract for Novo Nordisk's drug manufacturing facility in Clayton.
Despite pricing pressure & competition, the diabetes market remains lucrative given the prevalence of the disease and demand for better treatments. Novo Nordisk (NVO) is a key player in this market.
Categories: Yahoo FinanceGet free summary analysis Novo Nordisk A/S reports financial results for the quarter ended September 30, 2017. Highlights Summary numbers: Revenues of USD 4,203.06 million, Net Earnings of USD 1,542.94 million. Gross margins narrowed from 85.52% to 83.95% compared to the same period last year, operating (EBITDA) margins now 46.32% from 47.04%. Change in operating ... Read more (Read more...)
Allergan and Novo Nordisk offered Street-topping adjusted profit in the third quarter, though Allergan's sales were just in line.
Novo Nordisk A/S (NVO) reported third-quarter 2017 earnings of 63 cents per American Depositary Receipt (ADR) beating the Zacks Consensus Estimate of 58 cents. In fact, the reported figure was ahead of 57 cents earned a year ago.
Drugmaker Novo Nordisk forecast only muted growth in 2018 and warned that draft legislation in some U.S. states to make pricing more transparent could impact business in its largest market. The warning over U.S. state legislation comes after fears that President Donald Trump's healthcare policies could hurt the industry have diminished somewhat during the year. "Trump has repeated a number of times that he believes the industry gets away with murder, obviously we don't agree," said Lars Fruergaard Jorgensen, chief executive of the Danish company.
Drugmaker Novo Nordisk said on Wednesday that new legislation being prepared in some U.S. states to improve pricing transparency could potentially impact business in its key market. "If the transparency ...
COPENHAGEN (Reuters) - Denmark's Novo Nordisk, the world's top maker of diabetes drugs, posted third-quarter operating profit slightly above forecasts on Wednesday, and said it expected low to mid single-digit ...
Mads Krogsgaard Thomsen, the drugmaker’s chief science officer, is guiding the shift into medications for diabetes-related conditions.
Johnson & Johnson's (JNJ) Q3 earnings results were the key highlight this week with the company reporting strong results and raising its outlook.
WASHINGTON/COPENHAGEN, Oct 19 (Reuters) - Denmark's Novo Nordisk will take aim at Eli Lilly in the growing diabetes market after an advisory panel to the U.S. Food and Drug Administration (FDA) gave the green light to its semaglutide drug. Shares in Novo Nordisk rose almost 3 percent in early trading on Thursday, after the panel late on Wednesday concluded semaglutide is effective, reasonably safe and should be approved by the FDA. The panel voted 16-0 with one abstention in favor of the drug being approved.
Novo Nordisk A/S's new diabetes drug semaglutide is effective, reasonably safe and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday. The FDA typically follows the recommendations of its advisors. Novo Nordisk is hoping that semaglutide, administered through a once-weekly injection, will take market share from Eli Lilly & Co's once-weekly Trulicity, which in turn has been taking share from Novo Nordisk's once-daily Victoza.
Novo Nordisk A/S's closely watched diabetes drug semaglutide is effective, a preliminary review by the U.S. Food and Drug Administration concluded, sending the company's shares up 3.4 percent in premarket trading on Monday. The review, posted on the FDA's website on Monday, comes two days ahead of a meeting of advisors to the agency who will discuss the drug, semaglutide, and recommend whether it should be approved. The FDA typically follows the recommendations of its advisors.
Novo Nordisk (NVO) has a strong presence in the Diabetes care market and the current quarter has seen some events happening for the company that bode well for its growth.
The FDA approval of Mylan's (MYL) generic version of Teva's Copaxone was the main news this week. Allergan was also in the headlines related to its deal with the Saint Regis Mohawk Tribe.
Novo Nordisk's (NVO) fast-acting mealtime insulin aspart, Fiasp, has been approved by the FDA for the treatment of adults with diabetes.
The U.S. Food and Drug Administration on Friday approved Novo Nordisk's fast-acting insulin to treat diabetes. The product, known as Fiasp, is designed to help diabetics control post-meal spikes in blood sugar. Fiasp, or faster acting insulin asparte, is designed to work faster than existing fast-acting insulin such as Eli Lilly and Co's Humalog and Novo Nordisk's own NovoLog, known as NovoRapid outside the United States.
Partnerships with cities to change the way we manage our health are a long-term solution to the obesity and diabetes epidemic, Jesper Brandgaard said.